Journal of Clinical Oncology,
Journal Year:
2023,
Volume and Issue:
41(36), P. 5569 - 5578
Published: Sept. 26, 2023
To
evaluate
the
efficacy
and
safety
of
tucatinib
trastuzumab
in
patients
with
previously
treated
human
epidermal
growth
factor
receptor
2-positive
(HER2+)
metastatic
biliary
tract
cancer
(mBTC).
The Lancet Regional Health - Europe,
Journal Year:
2025,
Volume and Issue:
50, P. 101170 - 101170
Published: Feb. 19, 2025
In
recent
years,
treatment
options
for
patients
with
advanced
biliary
tract
cancer
(BTC)
have
increased
significantly
due
to
the
positive
results
from
phase
2/3
clinical
trials
of
immune
checkpoint
inhibitors,
combined
chemotherapy,
and
molecularly
targeted
agents.
These
advances
led
need
molecular
testing
identify
actionable
alterations
amenable
therapies.
However,
these
improvements
brought
them
many
questions
challenges,
including
identification
resistance
mechanisms
therapeutic
sequences.
this
Series
paper
we
aim
provide
an
overview
current
systemic
BTC,
highlighting
disparities
in
access
innovative
treatments
across
European
countries,
which
lead
inequalities
possibilities
treating
BTC.
We
also
discuss
how
ongoing
collaborative
projects,
such
as
COST
Action
Precision-BTC-Network
CA22125,
supported
by
(European
Cooperation
Science
Technology),
linked
Network
Study
Cholangiocarcinoma
(ENSCCA),
can
help
overcome
improve
scenario.
Gut,
Journal Year:
2023,
Volume and Issue:
73(1), P. 16 - 46
Published: Sept. 28, 2023
These
guidelines
for
the
diagnosis
and
management
of
cholangiocarcinoma
(CCA)
were
commissioned
by
British
Society
Gastroenterology
liver
section.
The
guideline
writing
committee
included
a
multidisciplinary
team
experts
from
various
specialties
involved
in
CCA,
as
well
patient/public
representatives
AMMF
(the
Cholangiocarcinoma
Charity)
PSC
Support.
Quality
evidence
is
presented
using
Appraisal
Guidelines
Research
Evaluation
(AGREE
II)
format.
recommendations
arising
are
to
be
used
guidance
rather
than
strict
protocol-based
reference,
patients
with
CCA
often
complex
always
requires
individual
patient-centred
considerations.
Clinical Cancer Research,
Journal Year:
2023,
Volume and Issue:
30(4), P. 836 - 848
Published: Dec. 7, 2023
Abstract
Purpose:
Genomic
rearrangements
can
generate
potent
oncogenic
drivers
or
disrupt
tumor
suppressor
genes.
This
study
examines
the
landscape
of
fusions
and
detected
by
liquid
biopsy
(LBx)
circulating
DNA
(ctDNA)
across
different
cancer
types.
Experimental
Design:
LBx
from
53,842
patients
with
66
solid
types
were
profiled
using
FoundationOneLiquid
CDx,
a
hybrid-capture
sequencing
platform
that
queries
324
cancer-related
Tissue
biopsies
(TBx)
FoundationOneCDx
used
as
comparator.
Results:
Among
all
LBx,
7,377
(14%)
had
≥1
pathogenic
rearrangement
detected.
A
total
3,648
(6.8%)
gain-of-function
(GOF)
oncogene
rearrangement,
4,428
(8.2%)
loss-of-function
Cancer
higher
prevalence
GOF
included
those
canonical
fusion
drivers:
prostate
(19%),
cholangiocarcinoma
(6.4%),
bladder
(5.5%),
non–small
cell
lung
(4.4%).
Although
driver
was
lower
in
than
TBx
overall,
frequency
detection
comparable
fraction
(TF)
≥1%.
Rearrangements
FGFR2,
BRAF,
RET,
ALK,
types,
but
tended
to
be
clonal
variants
some
potential
acquired
resistance
others.
Conclusions:
In
contrast
prior
literature,
this
reports
wide
variety
ctDNA.
The
tissue
when
TF
presents
viable
alternative
is
not
available,
there
may
less
value
confirmatory
testing
sufficient.
Journal of Clinical Medicine,
Journal Year:
2024,
Volume and Issue:
13(14), P. 4189 - 4189
Published: July 18, 2024
The
leading
cause
of
cancer
deaths
worldwide
is
attributed
to
non-small
cell
lung
(NSCLC),
necessitating
a
continual
focus
on
improving
the
diagnosis
and
treatment
this
disease.
In
review,
latest
breakthroughs
emerging
trends
in
managing
NSCLC
are
highlighted.
Major
advancements
diagnostic
methods,
including
better
imaging
technologies
utilization
molecular
biomarkers,
discussed.
These
have
greatly
enhanced
early
detection
personalized
plans.
Significant
improvements
patient
outcomes
been
achieved
by
new
targeted
therapies
immunotherapies,
providing
hope
for
individuals
with
advanced
NSCLC.
This
review
discusses
persistent
challenges
accessing
treatments
their
associated
costs
despite
recent
progress.
Promising
research
into
therapies,
such
as
CAR-T
therapy
oncolytic
viruses,
which
could
further
revolutionize
treatment,
also
aims
inform
inspire
continued
efforts
improve
patients
globally,
offering
comprehensive
overview
current
state
future
possibilities.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(16), P. 8594 - 8594
Published: Aug. 6, 2024
Liquid
biopsy,
a
noninvasive
diagnosis
that
examines
circulating
tumor
components
in
body
fluids,
is
increasingly
used
cancer
management.
An
overview
of
relevant
literature
emphasizes
the
current
state
liquid
biopsy
applications
care.
Biomarkers
particularly
DNA
(ctDNA),
RNAs
(ctRNA),
cells
(CTCs),
extracellular
vesicles
(EVs),
and
other
components,
offer
promising
opportunities
for
early
diagnosis,
treatment
selection,
monitoring,
disease
assessment.
The
implementation
precision
medicine
has
shown
significant
potential
various
types,
including
lung
cancer,
colorectal
breast
prostate
cancer.
Advances
genomic
molecular
technologies
such
as
next-generation
sequencing
(NGS)
digital
polymerase
chain
reaction
(dPCR)
have
expanded
utility
enabling
detection
somatic
variants
actionable
alterations
tumors.
also
demonstrated
predicting
responses,
monitoring
minimal
residual
(MRD),
assessing
heterogeneity.
Nevertheless,
standardizing
techniques,
interpreting
results,
integrating
them
into
clinical
routine
remain
challenges.
Despite
these
challenges,
implications
management,
offering
dynamic
approach
to
understanding
biology
guiding
personalized
strategies.
European Journal of Cancer,
Journal Year:
2024,
Volume and Issue:
200, P. 113587 - 113587
Published: Feb. 6, 2024
Background
Pemigatinib
is
approved
for
patients
with
pretreated,
locally
advanced
or
metastatic
CCA
harboring
FGFR2
rearrangements
fusions.
We
aim
to
assess
the
effectiveness
and
safety
of
pemigatinib
in
real-world
setting.
Material
Methods
A
joint
analysis
two
multicentre
observational
retrospective
cohort
studies
independently
conducted
France
Italy
was
performed.
All
consecutive
FGFR2-positive
affected
by
treated
as
second-
further
line
systemic
treatment
clinical
practice,
within
outside
European
Expanded
Access
Program,
were
included.
Results
Between
July
2020
September
2022,
72
14
Italian
25
French
Centres.
Patients
had
a
median
age
57
years,
76%
female,
81%
ECOG-PS
0-1,
99%
intrahepatic
CCA,
74%
≥
2
sites,
67%
disease
at
diagnosis,
while
38.8%
received
previous
lines
treatment.
At
data
cut-off
(April
2023),
ORR
DCR
45.8%
84.7%,
respectively.
Median
DoR
7
months
(IQR:
5.8-9.3).
Over
follow-up
time
19.5
months,
PFS
1-year
rate
8.7
32.8%.
OS
17.1
60.6%.
Fatigue
(69.4%),
ocular
toxicity
(68%),
nail
toxicities
(61.1%),
dermatologic
(41.6%)
hyperphosphataemia
(55.6%),
stomatitis
(48.6%),
diarrhea
(36.1%)
most
frequent,
mainly
G1-G2
AEs.
Overall
incidence
G3
AEs
22.2%,
no
patient
experienced
G4
AE.
Dose
reduction
temporary
discontinuation
needed
33.3%
40.3%
cases,
1
permanent
due
Conclusions
These
results
confirm
European Journal of Cancer,
Journal Year:
2024,
Volume and Issue:
203, P. 114046 - 114046
Published: April 12, 2024
For
decades,
treatment
of
advanced
biliary
tract
cancer
(BTC)
was
confined
to
the
use
chemotherapy.
In
recent
years
however,
number
therapeutic
options
available
for
patients
with
unresectable
BTC
have
drastically
increased,
immunotherapy
and
targeted
gradually
joining
ranks
guideline-recommended
regimens.The
aim
present
review
is
summarise
current
knowledge
on
focusing
epidemiology,
anatomical
distribution
strategies
systemic
treatment.
We
further
outline
ongoing
clinical
trials
provide
an
outlook
future
interventions.In
realm
gastrointestinal
malignancies,
increasing
finally
delivering
longstanding
commitment
personalised
oncology.
This
emphasises
need
considering
a
comprehensive
genomic-based
pathology
assessment
right
from
initial
diagnosis
fully
leverage
expanding
array
that
recently
become
accessible.
